Crossmark Global Holdings Inc. Sells 542 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Crossmark Global Holdings Inc. lowered its stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 13.1% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 3,585 shares of the company’s stock after selling 542 shares during the period. Crossmark Global Holdings Inc.’s holdings in Dr. Reddy’s Laboratories were worth $273,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of RDY. GAMMA Investing LLC increased its stake in shares of Dr. Reddy’s Laboratories by 54.7% during the first quarter. GAMMA Investing LLC now owns 721 shares of the company’s stock worth $53,000 after purchasing an additional 255 shares during the period. Contravisory Investment Management Inc. bought a new position in Dr. Reddy’s Laboratories during the 1st quarter worth $189,000. CWM LLC boosted its position in shares of Dr. Reddy’s Laboratories by 18.9% in the first quarter. CWM LLC now owns 2,584 shares of the company’s stock valued at $190,000 after acquiring an additional 410 shares during the period. Wealthstream Advisors Inc. bought a new stake in shares of Dr. Reddy’s Laboratories in the second quarter valued at about $203,000. Finally, Legacy Capital Group California Inc. bought a new position in Dr. Reddy’s Laboratories during the second quarter worth about $204,000. 14.02% of the stock is owned by institutional investors.

Dr. Reddy’s Laboratories Trading Up 0.8 %

RDY opened at $81.74 on Thursday. The stock has a market capitalization of $13.64 billion, a price-to-earnings ratio of 20.28, a P/E/G ratio of 1.84 and a beta of 0.56. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a twelve month low of $63.72 and a twelve month high of $84.46. The company has a 50-day simple moving average of $80.62 and a 200 day simple moving average of $75.47.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Saturday, July 27th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.10). The firm had revenue of $919.80 million for the quarter, compared to the consensus estimate of $861.68 million. Dr. Reddy’s Laboratories had a return on equity of 20.32% and a net margin of 19.28%. Analysts predict that Dr. Reddy’s Laboratories Limited will post 4.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 16th. Barclays increased their price target on Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.